Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023
July 25 2023 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, will release financial results for
the quarter ended June 30, 2023, before the market open on Monday,
August 7, 2023. John Aballi, Exagen’s President and Chief Executive
Officer, and Kamal Adawi, Chief Financial Officer, will host a
conference call to review the Company’s results at 8:30 AM ET (5:30
AM PT).
Interested parties may access the conference call by dialing
(201) 389-0918 (U.S.) or (877) 407-0890 (international).
Participants wishing to access the call via webcast should use the
link posted on the Exagen investor relations website at
investors.exagen.com.
A replay of the conference call will be available until Monday,
August 21, 2023, at 11:59 PM ET (8:59 PM PT). Interested parties
may access the replay of the conference call by dialing (201)
612-7415 (U.S.) or (877) 660-6853 (international) using passcode
13736103. Additionally, a recording of the webcast will be
available using the link on the Exagen investor relations website
approximately one hour after the call concludes.
About Exagen Inc.
Exagen is a leading provider of autoimmune diagnostic,
prognostic, and monitoring testing solutions. Exagen is a
patient focused, discovery driven organization built on the success
of AVISE® testing and is investing in its product pipeline to
support patients throughout their autoimmune diagnosis and
treatment journeys. The goal at Exagen is to assist patients,
physicians and payors by enabling precision
medicine. Exagen is located in San Diego County.
For more information, please visit Exagen.com and
follow @ExagenInc on Twitter.
CONTACTS:
Investor RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2024 to May 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From May 2023 to May 2024